The Medicines Company Licenses Alnylam’s RNAi Programme Targeting PCSK9
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 2 (Table of Contents)
Published: 12 Feb-2013
DOI: 10.3833/pdr.v2013.i2.1896 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
The Medicines Company (TMC) has licensed global rights to Alnylam Pharmaceuticals’ ALN-PCS RNAi therapeutic programme targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) for the treatment of hypercholesterolaemia...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS